Tata Capital Healthcare Fund (TCHF) is pivoting its exit strategy for its ₹2,500 crore third fund, with plans to return cash to investors for over 50% of portfolio companies through initial public offerings. According to Visalakshi Chandramouli, managing partner at the firm, this represents a significant shift from the fund's earlier approach of predominantly exiting via strategic acquisitions and secondary sales. The fund has made 20 investments so far and is currently raising its third fund with a ₹2,500 crore corpus, including a green-shoe option, after making a first close this year. This strategic pivot comes as the broader healthcare investment ecosystem demonstrates growing confidence in public market exits, with recent developments showing that NephroPlus IPO was oversubscribed 14 times and is currently 35% above its listing price, proving that inclusive healthcare models can generate both measurable impact and attractive financial returns.
The fund's average ticket sizes have increased substantially to $20-22 million from the previous $10-15 million, enabling the firm to source deals between $30-50 million. As reported by Mint, TCHF has been the lead investor in all 20 investments to date and will now collaborate with other funds or co-invest with limited partners for larger deals. The fund's capital structure includes Tata Capital as the sponsor and anchor investor, with approximately 90% of capital being raised from domestic and global institutions, as well as family offices. Historically, 40-45% of fund pool has been raised from healthcare and impact-focused investors. This collaborative approach aligns with broader industry trends, as the I4H community now stewards nearly $14.8 billion in healthcare assets under management, demonstrating that public-private partnerships are essential for scaling healthcare investments effectively.
The fund's investment thesis centers on two core areas: consumption and competency. Beyond these core segments, TCHF is evaluating new healthcare areas including nutraceuticals, animal nutrition, medical devices, active pharmaceutical ingredients, regional multi-speciality hospitals, and senior care. According to Chandramouli, the firm will certainly invest in medical devices as it aligns with the India story, but remains cautious in health-tech due to profitability challenges. For the competency strategy, the fund targets top-tier Indian companies operating in CDMO (Contract Development and Manufacturing Organisation), medical devices, export of pharmaceuticals, and similar sectors. The fund's approach focuses on identifying spaces where there is unmet healthcare need through disease, demographics, or geographical reach that companies' offerings can solve, with particular emphasis on single-specialty care delivery, now 20% of market share and growing at 10% CAGR, where PE deals are rising from 10% to 30% of the space.
TCHF has raised over $400 million across two funds, including co-investments, with 20 companies and 8 exits to date. The firm has invested in companies like Intas Biopharmaceuticals, Novalead Pharma, and Amanta from the first fund, and Linux Laboratories, Atulaya Healthcare, and Noble Plus Pharmacy from the second fund. As reported by Mint, the firm aims to identify companies that can expand at double the growth of the sector with preferred liquidity events through IPOs within a 5-6 year horizon. The fund's first investment from the third fund was made in Tenet Diagnostics last month. Looking ahead, the I4H community has generated unique insights into what it takes to invest inclusively in healthcare, with 93% of members reporting improvements in their own portfolio compared to 91% for the broader ecosystem, demonstrating that private capital can indeed fill critical gaps in healthcare delivery. The community's own data shows that members intend to make an average of five new investments per organization in 2026, suggesting continued growth but at an incremental pace.
The fund's approach focuses on identifying spaces where there is unmet healthcare need through disease, demographics, or geographical reach that companies' offerings can solve. From a consumption standpoint, TCHF evaluates companies generating cash flows from the home market, including hospitals, diagnostics, branded pharmaceuticals, med-tech and health-tech catering to domestic markets. The firm remains cautious on emerging segments like senior care, as the market has not fully developed yet, though it recognizes the importance of early movers in this space. The broader healthcare investment landscape shows that access to healthcare (volume of patients) stands out as the strongest area with 93% of members reporting improvements, while quality of care and health outcomes also scored strongly at 93% and 85% respectively. However, reaching the most marginalized communities and achieving systemic affordability remain the hardest challenges, requiring systematic commitment to building healthcare management capabilities and workforce development programs. The report also emphasizes that technology succeeds when it strengthens systems rather than attempts to replace them, with the future of healthcare innovation in emerging markets being defined by technology that extends the reach of scarce clinical talent and integrates fragmented systems.
